Table 1. Novel Psoralen Library.
A library of 73 novel psoralen derivatives was synthesized. Structures and cytotoxicities (± UV) are provided.
| Cytotoxicity Rank | Identifier | Structure | Cell Survival (%), No UVA | Cell Survival (%), + 1J UVA |
|---|---|---|---|---|
| 19 | 1A |  |
96.6 ± 1.9% | 27.6 ± 3.0% |
| 46 | 2A |  |
91.7 ± 4.1% | 91.5 ± 3.5% |
| 54 | 3A |  |
99.8 ± 3.3% | 95.4 ± 2.4% |
| 63 | 4A |  |
96.4 ± 2.3% | 98.9 ± 3.5% |
| 69 | 5A |  |
97.2 ± 4.0% | 102.8 ± 3.9% |
| 70 | 6A |  |
101.5 ± 2.9% | 105.0 ± 3.6% |
| 55 | 7A |  |
99.2 ± 3.6% | 95.4 ± 3.2% |
| 29 | 8A |  |
97.1 ± 2.5% | 71.0 ± 4.4% |
| 62 | 9A |  |
89.2 ± 2.9% | 97.1 ± 3.0% |
| 59 | 10A |  |
92.3 ± 2.8% | 96.5 ± 4.7% |
| 11 | 1B |  |
93.1 ± 4.6% | 2.20 ± 0.81% |
| 27 | 2B |  |
100.7 ± 3.0% | 70.7 ± 3.0% |
| 10 | 3B |  |
106.3 ± 3.4% | 1.60 ± 0.69% |
| 56 | 4B |  |
99.4 ± 4.6% | 95.6 ± 4.3% |
| 17 | 5B |  |
98.7 ± 4.8% | 21.4 ± 3.7% |
| 16 | 6B |  |
109.6 ± 5.2% | 8.6 ± 1.7% |
| 14 | 7B |  |
95.8 ± 4.0% | 3.6 ± 1.5% |
| 15 | 8B |  |
97.2 ± 6.2% | 4.1 ± 2.2% |
| 22 | 9B |  |
96.5 ± 2.8% | 39.4 ± 1.2% |
| 35 | 10B |  |
82.2 ± 7.4% | 83.7 ± 8.0% |
| 33 | 1C |  |
107.5 ± 4.8% | 83.4 ± 5.4% |
| 47 | 2C |  |
110.5 ± 5.9% | 91.7 ± 3.6% |
| 64 | 3C |  |
102.0 ± 3.0% | 99.8 ± 3.1% |
| 28 | 4C |  |
103.6 ± 3.3% | 70.9 ± 8.0% |
| 36 | 5C |  |
106.4 ± 4.4% | 83.9 ± 3.8% |
| 45 | 1D |  |
102.0 ± 4.2% | 90.5 ± 4.9% |
| 50 | 2D |  |
107.8 ± 5.2% | 93.6 ± 5.4% |
| 67 | 3D |  |
96.3 ± 4.9% | 102.7 ± 4.6% |
| 34 | 4D |  |
99.8 ± 4.4% | 83.5 ± 5.7% |
| 68 | 5D |  |
96.1 ± 4.8% | 102.7 ± 6.1% |
| 52 | 6D |  |
97.5 ± 5.1% | 94.4 ± 3.6% |
| 60 | 7D |  |
86.3 ± 3.9% | 96.6 ± 5.4% |
| 31 | 8D |  |
95.2 ± 4.8% | 79.2 ± 5.8% |
| 41 | 9D |  |
95.3 ± 4.6% | 89.2 ± 5.7% |
| 43 | 10D |  |
101.6 ± 5.5% | 90.1 ± 4.0% |
| 73 | 1E (Xanthotoxol) |  |
101.9 ± 3.6% | 111.6 ± 4.4% |
| 38 | 2E |  |
103.0 ± 2.9% | 85.7 ± 2.6% |
| 72 | 3E |  |
111.3 ± 4.2% | 108.2 ± 5.1% |
| 49 | 4E |  |
101.5 ± 5.8% | 93.0 ± 7.1% |
| 71 | 5E |  |
110.2 ± 4.3% | 107.7 ± 3.3% |
| 2 | 6E |  |
109.9 ± 5.4% | 0.23 ± 0.16% |
| 24 | 7E |  |
117.2 ± 3.5% | 54.0 ± 7.0% |
| 6 | 8E |  |
104.5 ± 4.0% | 0.62 ± 0.15% |
| 74 | 9E |  |
108.1 ± 3.8% | 112.6 ± 4.2% |
| 25 | 10E |  |
110.9 ± 4.7% | 60.4 ± 4.4% |
| 3 | 1F |  |
100.7 ± 3.9% | 0.43 ± 0.22% |
| 5 | 2F |  |
92.5 ± 1.9% | 0.50 ± 0.28% |
| 30 | 3F |  |
91.4 ± 3.7% | 71.2 ± 3.1% |
| 51 | 4F |  |
96.0 ± 2.5% | 94.0 ± 5.5% |
| 13 | 5F |  |
99.4 ± 4.2% | 2.7 ± 0.6% |
| 23 | 6F (Psoralen) |  |
97.4 ± 2.3% | 48.3 ± 3.6% |
| 26 | 7F |  |
103.8 ± 5.1% | 64.0 ± 6.0% |
| 8 | 8F |  |
97.1 ± 3.2% | 0.90 ± 0.35% |
| 57 | 9F |  |
99.2 ± 5.2% | 96.3 ± 3.1% |
| 66 | 10F |  |
90.9 ± 2.9% | 101.6 ± 2.4% |
| 40 | 1G |  |
94.3 ± 3.1% | 85.9 ± 3.8% |
| 44 | 2G |  |
85.8 ± 2.7% | 90.3 ± 3.5% |
| 39 | 3G |  |
88.5 ± 7.1% | 85.8 ± 4.2% |
| 12 | 4G |  |
86.8 ± 2.5% | 2.7 ± 1.0% |
| 37 | 5G |  |
103.4 ± 3.7% | 85.0 ± 6.6% |
| 9 | 6G |  |
105.5 ± 5.2% | 0.94 ± 0.47% |
| 42 | 7G |  |
95.2 ± 5.8% | 89.5 ± 6.0% |
| 61 | 8G |  |
103.2 ± 5.1% | 96.9 ± 4.6% |
| 53 | 9G |  |
93.9 ± 4.7% | 95.0 ± 6.4% |
| 58 | 10G |  |
98.6 ± 3.7% | 96.3 ± 2.1% |
| 18 | 1H |  |
92.8 ± 2.4% | 22.1 ± 3.4% |
| 32 | 2H |  |
94.1 ± 4.1% | 81.2 ± 3.0% |
| 48 | 3H |  |
92.5 ± 2.3% | 92.4 ± 2.8% |
| 7 | 4H |  |
97.5 ± 5.1% | 0.85 ± 0.37% |
| 20 | 5H |  |
93.4 ± 4.8% | 31.1 ± 4.7% |
| Control Compounds | ||||
| 65 | DMSO | - | 100.0 ± 4.6% | 101.3 ± 4.6% |
| 1 | TMP |  |
103.6 ± 3.6% | 0.15 ± 0.15% |
| 4 | AMT |  |
103.3 ± 2.8% | 0.43 ± 0.22% |
| 21 | 8-MOP |  |
88.1 ± 2.8% | 31.3 ± 3.7% |
